Cytophenix is developing rapid antimicrobial susceptibility tests that offer accurate and timely results, with the mission of enhancing treatment recommendations for patients with serious life-threatening infections.
Cytophenix’s innovative approach expedites the testing process without compromising accuracy. By swiftly identifying the most effective antibiotics for individual patients, informed treatment decisions can be made sooner.
With a team of seasoned researchers, clinicians, and engineers, Cytophenix is committed to transforming patient care by reducing the time to tailored treatment recommendations. By improving the speed and accuracy of antimicrobial susceptibility testing, Cytophenix is poised to make a significant impact on the management of serious infections, saving lives and optimising patient outcomes.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Perth, Western Australia, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Perth, Western Australia
Cytophenix Questions
Cytophenix's LinkedIn profile is https://au.linkedin.com/company/cytophenix
Cytophenix has
8 employees.
View email and phone details for 8
employees at Cytophenix.
Cytophenix's industry is
Biotechnology Research
Cytophenix's top competitors are
Silicon Quantum Computing,
Alkira Bio,
Infinite Bioworks,
Phrenix Therapeutics,
Three Springs Technology,
Brandon Capital,
Breaker,
Wild Yeast Zoo,
Advanced Strategic Capabilities Accelerator (Asca),
Myostellar.
Cytophenix's categories are Biotechnology Research
Cytophenix's founding year is 2023
